Flagship Pioneering: Vesalius Announces Multi-Target Strategic Alliance With GSK to Develop Breakthrough Treatments for People Afflicted With Parkinson's Disease
November 14, 2024
November 14, 2024
CAMBRIDGE, Massachusetts, Nov. 14 (TNSres) -- Flagship Pioneering, a bioplatform innovation company, issued the following news release on Nov. 12, 2024:
* * *
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson's Disease
GSK has Licensed a Preclinical Small Molecule Inhibitor Program
* * *
Vesalius Therapeutics, a company pioneering a r . . .
* * *
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson's Disease
GSK has Licensed a Preclinical Small Molecule Inhibitor Program
* * *
Vesalius Therapeutics, a company pioneering a r . . .